New combo therapy shows promise for Tough-to-Treat cancers

NCT ID NCT04879849

Completed Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation therapy in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and find the best dose. Participants received radiation, then the drug combo every 3 weeks. The study is complete, and results help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cedars Sinai Medical Center

Duarte, California, 91010-3012, United States
Laura And Isaac Perlmutter Cancer Center

New York, New York, 10016-4744, United States
Providence Portland Medical Center

Portland, Oregon, 97213-2933, United States
University of Chicago

Chicago, Illinois, 60637-1443, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232-0021, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG SQUAMOUS CELL CARCINOMA OF HEAD AND NECK TRIPLE NEGATIVE BREAST NEOPLASMS